Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P. Tagawa ST, et al. Among authors: portella l. Clin Cancer Res. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9. Clin Cancer Res. 2019. PMID: 30301829 Free PMC article. Clinical Trial.
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P. Thadani-Mulero M, et al. Among authors: portella l. Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20. Cancer Res. 2014. PMID: 24556717 Free PMC article.
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators. Antonarakis ES, et al. Among authors: portella l. J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20. J Clin Oncol. 2017. PMID: 28632486 Free PMC article. Clinical Trial.
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, Anniciello AM, Monaco M, Cavalcanti E, Maiolino P, Romagnoli G, Arra C, Botti G, Gabriele L, Scala S. D'Alterio C, et al. Among authors: portella l. J Exp Clin Cancer Res. 2019 Oct 28;38(1):432. doi: 10.1186/s13046-019-1420-8. J Exp Clin Cancer Res. 2019. PMID: 31661001 Free PMC article.
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.
Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S. Neve Polimeno M, et al. Among authors: portella l. Cell Mol Immunol. 2015 Jul;12(4):474-82. doi: 10.1038/cmi.2014.102. Epub 2014 Nov 3. Cell Mol Immunol. 2015. PMID: 25363530 Free PMC article.
CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.
Ieranò C, Portella L, Lusa S, Salzano G, D'Alterio C, Napolitano M, Buoncervello M, Macchia D, Spada M, Barbieri A, Luciano A, Barone MV, Gabriele L, Caraglia M, Arra C, De Rosa G, Scala S. Ieranò C, et al. Among authors: portella l. Nanoscale. 2016 Apr 14;8(14):7562-71. doi: 10.1039/c5nr06335c. Nanoscale. 2016. PMID: 26983756
CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
Ieranò C, D'Alterio C, Giarra S, Napolitano M, Rea G, Portella L, Santagata A, Trotta AM, Barbieri A, Campani V, Luciano A, Arra C, Anniciello AM, Botti G, Mayol L, De Rosa G, Pacelli R, Scala S. Ieranò C, et al. Among authors: portella l. Cell Death Dis. 2019 Jul 22;10(8):562. doi: 10.1038/s41419-019-1796-6. Cell Death Dis. 2019. PMID: 31332163 Free PMC article.
CXCL12 Signaling in the Tumor Microenvironment.
Portella L, Bello AM, Scala S. Portella L, et al. Adv Exp Med Biol. 2021;1302:51-70. doi: 10.1007/978-3-030-62658-7_5. Adv Exp Med Biol. 2021. PMID: 34286441 Review.
51 results